arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Lineage Cell Therapeutics, Inc.

LCTX
$1.10 ▼ -0.04 (-3.93%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
7
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lineage Cell Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $269.5M
Dividend Yield
Revenue Growth 14.8%
Op. Margin -440.2%
ROIC -11.1%
FCF / Share $-0.03
Trailing P/E
Price / Book 5.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.73M
↑ +14.8%
Net Income Profit after all expenses
$-4.81M
↓ -16.3%
Operating Margin Operating profit as % of sales
-440.2%
↓ -344.2% 0th
FCF / Share Free cash flow per share
$-0.03
↓ -50.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
5
Financial Health
4
Cash Quality
33

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters